Description: Febuxostat is a potent, non-purine, selective inhibitor of xanthine oxidase, the enzyme that catalyzes the conversion of hypoxanthine to xanthine to uric acid. The inhibition of xanthine oxidase decreases the serum concentrations of uric acid.
It may be taken with or without food. It may be taken w/o regard to antacid use.
Patient with a history of hypersensitivity reaction to allopurinol; major CV disease (e.g. MI, stroke, unstable angina), ischaemic heart disease or CHF; thyroid disorders. Not to be started during an acute attack of gout; continue treatment if acute attacks occur in patients already receiving febuxostat, and treat the acute attack separately. Should only be used in patients who have an inadequate response to a maximally titrated allopurinol dose, who are intolerant to allopurinol, or when treatment with allopurinol is not advisable. Not recommended in organ transplant recipients, patients at increased risk of urate formation (e.g. Lesch-Nyhan syndrome, malignant disease, and its treatment), or for the treatment of asymptomatic hyperuricemia. Hepatic and severe renal impairment. Pregnancy and lactation.